What this site is — and what it is not

What this site is

Retatrutide Telehealth Digest keeps a documented dossier on retatrutide (LY3437943): it reads the peer-reviewed literature and records what the trials measured, with each entry traced to its source. It diagnoses, treats, and prescribes nothing. It runs no clinic and no pharmacy. It sells, supplies, and sources nothing. The writing is documentation of published science, and every quantitative claim carries its citation.

The word "telehealth" in the domain is a search term — it catches traffic from people looking for telehealth-related information about retatrutide. It does not describe what this site does. No healthcare service, consultation, prescription, or referral is offered here. The editorial name is "Retatrutide Telehealth Digest," and the operative work is the documentation.

What we publish and how

Every quantitative claim is documented to a specific peer-reviewed publication or registered clinical trial. Each page's reference index lists the full citation for every claim, with DOIs and PubMed links where available. Sources come from the published record — no proprietary databases, no gray-literature, nothing invented or unverifiable.

Community-reported effects (on the Effects page) are labeled anecdotal — unverified self-reports from research-use communities, not clinical evidence. The line between a peer-reviewed trial finding and a community report is kept explicit throughout.

The dossier covers one compound only: retatrutide, the investigational triple GIP/GLP-1/glucagon receptor agonist developed by Eli Lilly. Its pharmacokinetics emphasis — half-life, dosing windows, and the Phase 1b data behind them — follows the documented focus of the compound-corpus that informs the editorial selection.

What we are not

Not a telehealth provider. This dossier connects no one with a clinician and offers no consultations, treatment plans, or prescriptions.

Not a pharmacy. It dispenses, compounds, and supplies nothing — not retatrutide, not any compound.

Not a vendor. It sells nothing and links to no supplier of research-labeled material.

Not affiliated with Eli Lilly and Company. The research record documented here belongs to the public scientific literature; the commentary on it is unaffiliated.

Anyone looking for a healthcare provider for weight management or metabolic health should consult a licensed clinician.

On the investigational status of retatrutide

Every page restates the same foundational fact: retatrutide is investigational. It is not FDA-approved. It is approved nowhere. It cannot be prescribed or legally dispensed outside a clinical trial.

The dossier documents this consistently because the landscape around the compound is noisy — gray-market vendors, incomplete secondary reporting, and colloquial misnomers (like "GLP-3") circulate widely. The editorial purpose is to hold the record steady: what the trials measured, what was published, and where the genuine open questions remain.